Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Genzyme receives Refuse to File letter from FDA for LEMTRADA

Genzyme, a Sanofi company, announced it has received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) in response to the supplemental Biologics License Application (sBLA) for the approval of LEMTRADA (alemtuzumab) as a treatment for relapsing multiple sclerosis.

27 Aug 2012

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Roche has reported that updated results from its EMILIA Phase III trial show that patients treated with trastuzumab emtansine had a significant improvement in OS compared to those randomized to standard-of-care therapy.

27 Aug 2012

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Seattle Genetics, Inc. today announced the initiation of a phase Ib clinical trial evaluating SGN-75 in combination with everolimus (Afinitor) for patients with advanced metastatic renal cell carcinoma (RCC).

24 Aug 2012

Lilly’s solanezumab Phase 3 trials on AD do not meet primary endpoints

Eli Lilly and Company today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease.

24 Aug 2012

EMD Millipore enters definitive agreement to acquire Biochrom

EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany.

From Biochrom Ltd. 23 Aug 2012

Serum autoantibodies predict IgA nephropathy disease progression

Study findings reveal that increasing serum levels of immunoglobulin G and IgA autoantibodies act as markers for progression of IgA nephropathy.

22 Aug 2012

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

The hematology journal BLOOD published today a full-length article describing final Phase 2 data for Symphogen's rozrolimupab, a novel human recombinant mixture of 25 antibodies which all are manufactured simultaneously from a single batch.

22 Aug 2012

Radiation therapy alone no longer the best choice for early follicular lymphoma

A University of Rochester Medical Center study published in the Journal of Clinical Oncology, challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient is carefully examined and staged at diagnosis.

22 Aug 2012

FDA extends action date for Pfizer’s tofacitinib NDA review

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA).

22 Aug 2012

NIAID announces 14 grants for basic research to identify new HIV vaccine approaches

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine.

22 Aug 2012

GM-CSF depletion suppresses pain in people with arthritis-related conditions

The research relates to a family of molecules firstly discovered in Melbourne that applied to blood cell development. One of these, granulocyte macrophage colony-stimulating factor or GM-CSF, acts as a messenger between cells acting at a site of inflammation.

22 Aug 2012

New silicon chips help identify patients with lupus

Researchers at the Stanford University School of Medicine and Intel Corp. have collaborated to synthesize and study a grid-like array of short pieces of a disease-associated protein on silicon chips normally used in computer microprocessors.

21 Aug 2012

FSH-specific polyclonal antibody might offer more effective way to prevent osteoporosis

A new study suggests that a polyclonal antibody that blocks follicle-stimulating hormone (FSH) in mice without ovaries might offer a more effective way to prevent or arrest osteoporosis than currently available treatments.

21 Aug 2012

New attack on arthritis pain

A research team from the University of Melbourne is working on a new therapy that can potentially control the pain caused by diseases such as rheumatoid arthritis and osteoarthritis.

21 Aug 2012

FibeBiotics aims to prove benefits of polysaccharides in clinical trials

Staying healthy requires constantly stimulating the immune system. Ingesting non-digestible fibres such as polysaccharides is thought to help. Yet companies including such ingredients in their food products cannot claim that they boost the immune system. At least, not until they have been scientifically tested and proven in clinical trials. Only then, would the European Food Safety Agency (EFSA) allow such health claims.

18 Aug 2012

Increasing blood levels of particular proteins may act as warning signs for IgA nephropathy

Increasing blood levels of particular proteins may act as warning signs for patients with one of the most common diseases of the kidney, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

17 Aug 2012

Mepolizumab almost halves exacerbations in severe asthma patients

The largest study of patients with severe asthma to date, published in The Lancet special issue on respiratory medicine, shows that those treated with the monoclonal antibody mepolizumab experienced an almost 50% reduction in severe exacerbations, emergency room visits, and hospitalisations compared with patients given placebo.

17 Aug 2012

CDC recommends hepatitis C screening for all patients born from 1945-1965

Without other risk factors, all Americans born between 1945 and 1965 should have a one-time screening for the hepatitis C virus (HCV) according to new recommendations being published early online today in Annals of Internal Medicine, the flagship journal of the American College of Physicians. The Centers for Disease Control and Prevention (CDC) also recommends that all persons identified with HCV should receive a brief alcohol screening and intervention and be referred to appropriate care and treatment services for HCV and related conditions.

17 Aug 2012

Plexin B2-CD100 interaction for prompt activation of γδ T cells and wound healing

Scientists at The Scripps Research Institute have made a breakthrough in understanding a class of cells that help wounds in skin and other epithelial tissues heal, uncovering a molecular mechanism that pushes the body into wound-repair mode.

17 Aug 2012

Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection

Genocea Biosciences announced today that it has initiated a Phase 1/2a clinical study with its lead candidate, GEN-003. GEN-003 is an investigational vaccine designed to stimulate T cell and B cell immune responses to potentially reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe Herpes Simplex Virus type 2 (HSV-2) infection.

16 Aug 2012

Antibody News and Research

Further Reading

Genzyme receives Refuse to File letter from FDA for LEMTRADA

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Lilly’s solanezumab Phase 3 trials on AD do not meet primary endpoints

EMD Millipore enters definitive agreement to acquire Biochrom

Serum autoantibodies predict IgA nephropathy disease progression

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

Radiation therapy alone no longer the best choice for early follicular lymphoma

FDA extends action date for Pfizer’s tofacitinib NDA review

NIAID announces 14 grants for basic research to identify new HIV vaccine approaches

GM-CSF depletion suppresses pain in people with arthritis-related conditions

New silicon chips help identify patients with lupus

FSH-specific polyclonal antibody might offer more effective way to prevent osteoporosis

New attack on arthritis pain

FibeBiotics aims to prove benefits of polysaccharides in clinical trials

Increasing blood levels of particular proteins may act as warning signs for IgA nephropathy

Mepolizumab almost halves exacerbations in severe asthma patients

CDC recommends hepatitis C screening for all patients born from 1945-1965

Plexin B2-CD100 interaction for prompt activation of γδ T cells and wound healing

Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News